Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer ’s disease: study protocol for a randomised controlled trial (ELAD study)

DiscussionAlzheimer ’s disease is a leading cause of morbidity worldwide. As available treatments are only symptomatic, the search for disease-modifying therapies is a priority. If the ELAD trial is successful, liraglutide and GLP-1 analogues will represent an important class of compounds to be further evaluated in c linical trials for Alzheimer’s treatment.Trial registrationClinicalTrials.gov,NCT01843075. Registration 30 April 2013.
Source: Trials - Category: Research Source Type: clinical trials